

Amendments to the Claims

1. (Canceled)

2. (Currently amended) An isolated peptide having at least 10 synthetic amino acid acids of the sequence:

~~(a) DCSQDCAACS ILARPAELNT ETCILECAGK LSSNDTEGGL CKEFLHPSKV DLPR (SEQ ID NO:1); or~~

~~(b) DCSQDCAACS ILARPAELNT ETCILECEGK LSSNDTEGGL CKEFLHPSKV DLPR (SEQ ID NO:2), wherein the peptide has paralytic activity.~~

3. (Currently amended) The peptide of claim ~~claims 1 or 2~~, which includes at least one cysteine amino acid having a sulfhydryl group.

4. (Original) The peptide of claim 3, comprising at least two cysteine amino acids each having a sulfhydryl group and forming a disulfhydryl bond.

5. (Original) The peptide of claim 4, comprising six cysteine amino acids each having a sulfhydryl group and forming three disulfhydryl bonds.

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Canceled)

10. (Currently amended) The peptide of claim ~~claims 1 or 2~~, in a purified form.

11. (Currently amended) The peptide of claim ~~claims 1 or 2~~, purified at least 90%, 95% or 99%.

12. (Currently amended) An isolated peptide comprising a fragment of ~~5-10~~, 10-15, 15-20, or 20-24 amino acids of the peptide of claim ~~claims 1 or 2~~.
13. (Currently amended) A pharmaceutical composition or cosmetic composition including the peptide of claim 2 ~~any one of claims 1-12~~.
14. (Canceled)
15. (Canceled)
16. (Canceled)
17. (Canceled)
18. (Canceled)
19. (Canceled)
20. (Canceled)
21. (Canceled)
22. (Original) A method of medical treatment of migraine, myofacial and other types of pain, muscle tremors, neuromuscular diseases, and excessive sweating in a mammal in need thereof comprising administering to the mammal the pharmaceutical composition of claim 13.
23. (Currently amended) A method of providing analgesia or neuromuscular blocking in a mammal comprising administering to the mammal a composition comprising a peptide including all or part of the amino acid sequence ~~the pharmaceutical composition of claim 13~~ DCSQDCAACS ILARPAELNT ETCILECEGK LSSNDTEGGL CKEFLHPSKV DLPR (SEQ ID NO:2), wherein the peptide has paralytic activity.

24. (Currently amended) ~~A- The method for~~ of claim 23, wherein the analgesia comprises analgesia of a wound ~~in a mammal comprising administering to the mammal the pharmaceutical composition of claim 13.~~
25. (Currently amended) A method of reducing wrinkles in a mammal comprising administering to the mammal a composition comprising a peptide including all or part of the amino acid sequence DCSQDCAACS ILARPAELNT ETCILECEGK LSSNDTEGGL CKEFLHPSKV DLPR (SEQ ID NO:2), wherein the peptide has paralytic activity~~the cosmetic composition of claim 13.~~
26. (Currently amended) An antibody to the peptide of claim ~~claims 1 or 2.~~
27. (Cancelled)
28. (Currently amended) A nucleic acid encoding the peptide of claim ~~claims 1 or 2.~~
29. (New) The nucleic acid of claim 28, comprising a synthetic nucleic acid.
30. (New) An isolated peptide comprising at least 80% sequence identity with the amino acid sequence of (SEQ ID NO: 2), wherein the peptide comprises a synthetic peptide having paralytic activity.
31. (New) The peptide of claim 2, comprising the sequence DCSQDCAACS ILARPAELNT ETCILECEGK LSSNDTEGGL CKEFLHPSKV DLPR (SEQ ID NO:2), wherein the peptide has paralytic activity.
32. (New) The method of claim 23, wherein the peptide comprises a synthetic peptide.
33. (New) The method of claim 25, wherein the peptide comprises a synthetic peptide.